Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions

 
• By Dean Rudge

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Dollars
Amneal is pleased that recent FDA guidelines have contributed to lower biosimilar development costs • Source: Shutterstock

More from Biosimilars

More from Products